18.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$18.55
Aprire:
$18.25
Volume 24 ore:
1.01M
Relative Volume:
1.19
Capitalizzazione di mercato:
$1.74B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-13.21
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
+18.74%
1M Prestazione:
-1.44%
6M Prestazione:
+10.51%
1 anno Prestazione:
+51.27%
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Confronta NVCR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NVCR
Novocure Ltd
|
18.50 | 1.74B | 577.74M | -149.78M | -78.21M | -1.40 |
![]()
ABT
Abbott Laboratories
|
128.85 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
101.90 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
![]()
SYK
Stryker Corp
|
365.06 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
84.16 | 107.92B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
76.04 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2023-11-20 | Ripresa | JP Morgan | Neutral |
2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2023-08-04 | Iniziato | SVB Securities | Outperform |
2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-01-05 | Reiterato | H.C. Wainwright | Buy |
2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
2022-05-16 | Iniziato | H.C. Wainwright | Buy |
2022-02-08 | Iniziato | Loop Capital | Buy |
2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
2022-01-20 | Aggiornamento | Truist | Hold → Buy |
2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
2021-01-25 | Reiterato | Piper Sandler | Overweight |
2020-09-23 | Iniziato | Northland Capital | Outperform |
2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-09-17 | Downgrade | Truist | Buy → Hold |
2020-06-01 | Ripresa | Oppenheimer | Perform |
2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
2019-03-20 | Iniziato | SunTrust | Hold |
2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
2018-07-16 | Iniziato | Evercore ISI | Outperform |
2018-04-18 | Reiterato | Mizuho | Buy |
2018-02-23 | Reiterato | Mizuho | Buy |
2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2016-07-29 | Reiterato | Wedbush | Outperform |
2016-01-19 | Iniziato | Barclays | Underweight |
2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com
H.C. Wainwright maintains Buy on NovoCure, $38 price target - Investing.com
NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey
NovoCure (NASDAQ:NVCR) Cut to “Sell” at StockNews.com - Defense World
NovoCure: Q1 Earnings Snapshot - Huron Daily Tribune
Bank of Montreal Can Buys New Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure’s Q1 2025: Revenue Growth and Strategic Advances - TipRanks
NovoCure Ltd. Earnings Call: Growth Amid Financial Challenges - TipRanks
NovoCure (NVCR) Stock Rises on Strong Quarterly Earnings - GuruFocus
Novocure (NVCR) Sees Early Revenue from Lung Cancer Treatments | NVCR Stock News - GuruFocus
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 - Benzinga
Novocure’s device for metastatic NSCLC treatment gains CE Mark - MSN
NovoCure (NVCR) Reports Strong Q1 Revenue Growth Amid Optune Lua Expansion - GuruFocus
Stocks of NovoCure Ltd (NVCR) are poised to climb above their peers - Sete News
NovoCure Surpasses Q1 Expectations - Mitrade
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
NovoCure Surpasses Q1 Expectations - The Motley Fool
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats E - GuruFocus
Novocure Ltd earnings beat by $0.18, revenue topped estimates - Investing.com India
Novocure (NVCR) Surpasses Q1 Revenue Projections, Reports $154.99M | NVCR Stock News - GuruFocus
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats Estimate, Revenue of $155 Million Exceeds Expectations - GuruFocus
Novocure Reports First Quarter 2025 Financial Results | NVCR Stock News - GuruFocus
Novocure Reports First Quarter 2025 Financial Results - TradingView
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025 - TipRanks
NovoCure's Earnings: A Preview - Benzinga
Novocure (NVCR) to Showcase Key PANOVA-3 Trial Findings at ASCO 2025 | NVCR Stock News - GuruFocus
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical T - GuruFocus
Novocure price target lowered to $34 from $42 at Piper Sandler - TipRanks
Novocure (NVCR) Faces Revised Price Target Amid Investor Opportunities | NVCR Stock News - GuruFocus
Novocure sees 6% spike from EU nod for electric lung cancer therapy gadget - Mugglehead Magazine
Novocure (NVCR) Gains CE Mark for Optune Lua in Lung Cancer Treatment | NVCR Stock News - GuruFocus
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer | NVCR Stock News - GuruFocus
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer - Yahoo Finance
LPL Financial LLC Acquires Shares of 27,861 NovoCure Limited (NASDAQ:NVCR) - Defense World
Wedbush Issues Pessimistic Forecast for NovoCure Earnings - Defense World
NovoCure (NASDAQ:NVCR) vs. Sonoma Pharmaceuticals (NASDAQ:SNOA) Financial Review - Defense World
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Why NovoCure Stock Was Withering on Wednesday - MSN
NovoCure (NASDAQ:NVCR) Upgraded to “Hold” at StockNews.com - Defense World
Why NovoCure (NVCR) Stock Fell Today - GuruFocus
Novocure price target lowered to $27 from $29 at Wedbush - TipRanks
Wedbush Adjusts Price Target for Novocure (NVCR) Ahead of Earnings Report | NVCR Stock News - GuruFocus
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price - Defense World
11,672 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Raymond James Financial Inc. - Defense World
NovoCure Escapes Investor Suit Over Cancer Therapy Trial Data - Bloomberg Law News
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com - Defense World
NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week - simplywall.st
Thrivent Financial for Lutherans Reduces Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):